Immune Design Corp. (NASDAQ:IMDZ) Director Lewis W. Coleman purchased 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The stock was bought at an average cost of $6.25 per share, with a total value of $250,000.00. Following the acquisition, the director now owns 50,000 shares of the company’s stock, valued at approximately $312,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Immune Design Corp. (NASDAQ:IMDZ) opened at 7.10 on Wednesday. The company has a 50-day moving average price of $7.07 and a 200 day moving average price of $10.26. Immune Design Corp. has a 12 month low of $6.02 and a 12 month high of $23.55. The stock’s market capitalization is $143.24 million.

Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.03. Immune Design Corp. had a negative net margin of 525.30% and a negative return on equity of 44.57%. Equities analysts predict that Immune Design Corp. will post ($2.70) earnings per share for the current year.

A number of large investors have recently made changes to their positions in the stock. Pictet Asset Management Ltd. raised its stake in shares of Immune Design Corp. by 768.9% in the second quarter. Pictet Asset Management Ltd. now owns 748,145 shares of the company’s stock worth $9,389,000 after buying an additional 662,045 shares in the last quarter. Abingworth LLP acquired a new stake in shares of Immune Design Corp. during the second quarter worth $1,610,000. JPMorgan Chase & Co. raised its stake in shares of Immune Design Corp. by 72.6% in the second quarter. JPMorgan Chase & Co. now owns 246,675 shares of the company’s stock worth $2,014,000 after buying an additional 103,750 shares in the last quarter. TFS Capital LLC raised its stake in shares of Immune Design Corp. by 94.4% in the second quarter. TFS Capital LLC now owns 102,685 shares of the company’s stock worth $838,000 after buying an additional 49,867 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Immune Design Corp. by 34.4% in the first quarter. State Street Corp now owns 168,119 shares of the company’s stock worth $2,190,000 after buying an additional 43,026 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors.

Several equities research analysts recently commented on IMDZ shares. Leerink Swann reaffirmed a “buy” rating on shares of Immune Design Corp. in a report on Friday, June 10th. Jefferies Group reaffirmed a “buy” rating and issued a $20.00 price target on shares of Immune Design Corp. in a report on Sunday, May 29th. Finally, Zacks Investment Research raised Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Friday, August 12th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Immune Design Corp. currently has a consensus rating of “Buy” and a consensus price target of $14.50.

About Immune Design Corp.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

5 Day Chart for NASDAQ:IMDZ

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.